Trying to lock in vendors who don't want to buy from China: Biocon CEO & MD

Siddharth Mittal, CEO & MD, Biocon, elaborates on his plans to grow this business further

Biocon’s generics and active pharmaceutical ingredients (API) business clocked 18 per cent year-on-year (YoY) growth in Q2FY23. Generics account for roughly 26 per cent of the company’s consolidated turnover. Siddharth Mittal, CEO & MD, Biocon, in an interview with Sohini Das, elaborates on his plans to grow this business further. Edited excerpts. 

Tell us about your plans to grow further in emerging markets?

Insulin is largely a tender-based product in many emerging markets. These markets have been growing for the past few years, and we expect this growth to continue, not only in insulin but also non-insulin products. For non-insulin